Immunitybio and nantomics announce clinical validation of a proprietary method to identify unique targets for immunotherapy in individual breast cancer patients

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a publicly traded immunotherapy company , and privately-held nantomics today announced publication of a stepwise approach or “pipeline” for identification and validation of neoepitope and neoepitope-reactive t cells from individual patients. the identification of neoepitopes—short peptide sequences that are mutated in tumors and are capable of generating an immune response—provides critical support in the successful develop
IBRX Ratings Summary
IBRX Quant Ranking